Fibrocell Science (FCSC) versus Inovio Pharmaceuticals (INO) Critical Review
Fibrocell Science (NASDAQ: FCSC) and Inovio Pharmaceuticals (NASDAQ:INO) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, institutional ownership, valuation and dividends.
Volatility & Risk
Fibrocell Science has a beta of 0.51, meaning that its stock price is 49% less volatile than the S&P 500. Comparatively, Inovio Pharmaceuticals has a beta of 2.91, meaning that its stock price is 191% more volatile than the S&P 500.
This table compares Fibrocell Science and Inovio Pharmaceuticals’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Insider and Institutional Ownership
54.7% of Fibrocell Science shares are held by institutional investors. Comparatively, 25.0% of Inovio Pharmaceuticals shares are held by institutional investors. 2.1% of Fibrocell Science shares are held by company insiders. Comparatively, 10.6% of Inovio Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term.
This is a breakdown of recent ratings and target prices for Fibrocell Science and Inovio Pharmaceuticals, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Fibrocell Science currently has a consensus price target of $5.53, suggesting a potential upside of 169.92%. Inovio Pharmaceuticals has a consensus price target of $20.20, suggesting a potential upside of 250.09%. Given Inovio Pharmaceuticals’ higher probable upside, analysts plainly believe Inovio Pharmaceuticals is more favorable than Fibrocell Science.
Valuation & Earnings
This table compares Fibrocell Science and Inovio Pharmaceuticals’ gross revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Price/Sales Ratio||NetIncome||Earnings Per Share||Price/Earnings Ratio|
|Fibrocell Science||$350,000.00||86.22||-$15.29 million||($1.96)||-1.05|
|Inovio Pharmaceuticals||$35.37 million||14.72||-$73.74 million||($1.08)||-5.34|
Fibrocell Science has higher revenue, but lower earnings than Inovio Pharmaceuticals. Inovio Pharmaceuticals is trading at a lower price-to-earnings ratio than Fibrocell Science, indicating that it is currently the more affordable of the two stocks.
Inovio Pharmaceuticals beats Fibrocell Science on 8 of the 13 factors compared between the two stocks.
Fibrocell Science Company Profile
Fibrocell Science, Inc. is an autologous cell and gene therapy company. The Company is focused on discovering and developing localized therapies for diseases affecting the skin, connective tissue and joints. Its product candidate, azficel-T, is in development to treat patients suffering from vocal cord scarring that is either idiopathic or age-related. It is investigating the indication in a Phase II clinical trial. Its gene-therapy product candidate, FCX-007, is in pre-clinical development for the treatment of recessive dystrophic epidermolysis bullosa. Its gene-therapy product candidate, FCX-013, is in pre-clinical development for the treatment of linear scleroderma. Its product, LAVIV (azficel-T), is indicated for the improvement of the appearance of moderate to severe nasolabial fold wrinkles in adults. A third gene-therapy program is focused on the treatment of arthritis. Its product, LAVIV (azficel-T), is focused on improving the appearance of nasolabial fold wrinkles in adults.
Inovio Pharmaceuticals Company Profile
Inovio Pharmaceuticals, Inc. (Inovio) is a clinical-stage pharmaceutical company, which is involved in developing deoxyribonucleic acid (DNA) immunotherapies and vaccines focused on treating and preventing cancers and infectious diseases. The Company’s DNA-based immunotherapies, in combination with its electroporation delivery devices, generates immune responses, in particular T cells, in the body to fight target diseases. It has completed, current or planned clinical programs of its SynCon immunotherapies for human papillomavirus (HPV)-caused pre-cancers and cancers, influenza, prostate cancer, breast/lung/pancreatic cancer, hepatitis C virus (HCV), hepatitis B virus (HBV), human immunodeficiency virus (HIV), Ebola, Middle East Respiratory Syndrome (MERS) and Zika virus. With its immunotherapy platform, as well as with its CELLECTRA electroporation delivery technology, it has a pipeline of pre-clinical and clinical stage products that have generated in vivo immune responses.
Receive News & Ratings for Fibrocell Science Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fibrocell Science Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.